



PRESS RELEASE

Berlin, 10 May 2017

BIONNALE 2017: Biologisation of Industry Brings Opportunities

Development of products and company mergers

There is a clear trend towards bio-based products across almost all industries and consumer sectors. At BIONNALE 2017, an international trade fair held on 17th May in Berlin, Dr. Martin Borchert will report on the significance of this biologisation for the biotechnology industry which has a strong base in Brandenburg and Berlin, and on the products which actually result from this process. Dr. Borchert, who majored in biotechnology and chemistry in Hamburg and Berlin, is Head of Microbial Diversity R&D at the Danish multinational Novozymes A/S.

The firm specialises in enzymes and collaborates with many notable biology and chemistry companies and acquired the German research and biotechnology company Organobalance last year. Martin Borchert is also responsible for integrating the two companies. Titled "Creating innovative bio-based products", his talk will focus on how the two players develop new enzyme and bacteria-based products, among others for the food, feed, and pharmaceutical industries.

"Bioactives such as industrial enzymes and microorganisms improve production efficiency and reduce energy and raw material inputs", Borchert explained in advance of the BIONNALE.

"The challenge we're facing is to develop new bio-based products based on our research and with the help of our several thousand bacterial strains", emphasises Prof. Dr. Christine Lang, Managing Director of Organobalance GmbH. The research and development activities of Novozymes and Organobalance provided an important contribution to an economy-wide biologisation. A good example was the strategic partnership with Boehringer Ingelheim for poultry hatcheries announced at the end of March this year

<http://www.novozymes.com/en/news/news-archive/2017/03/new-collaboration-in-probiotic-products-for-poultry-hatcheries>).

About Organobalance:

Organobalance GmbH is a biotechnology research and development company with facilities in Berlin and Flensburg. Founded in 2001, the firm develops and markets products based on probiotic bacteria cultures as well as yeast production strains for use in industrial biotechnology. One of its best-known products is Pylopass™, a natural lactobacillus agent against *Helicobacter pylori*, a stomach bacterium. Among the company's German and international customers are clients from the food, cosmetics, feed, agriculture, and pharmaceutical industries. The company owns an extensive collection of yeast and lactobacillus cultures, some of which date back to the 1920s. Christine Lang, the company's Managing Director, is also a Professor of Microbiology and Molecular Genetics at the TU Berlin and has received several business awards. She also chairs the German Bioeconomy Council. Since September 2016, Organobalance has become a part of the Danish company Novozymes A/S.



For further information:
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin, Germany
Phone +49 (0) 30 46307 200
Fax +49 (0) 30 46307 210
www.organobalance.com